Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Marta Araujo-Castro, Betina Biagetti, Edelmiro Menedez-Torre, Iría Novoa-Testa, Fernando Cordido, Eider Pascual-Corrales, Víctor Rodríguez Berrocal, Fernando Guerrero-Pérez, Almudena Vicente, Juan Carlos Percovich Hualpa, Rogelio Garcia Centeno, Laura González Fernández, María Dolores Ollero García, Ana Irigaray Echarri, María Dolores Moure Rodríguez, Cristina Novo-Rodríguez, María Calatayud, Rocío Villar, Ignacio Bernabéu, Cristina Alvarez-Escola, Pamela Benítez Valderrama, Carmen Tenorio, Pablo Abellán Galiana, Eva Venegas, Inmaculada González-Molero, Pedro Iglesias, Concepción Blanco-Carrera, Fernando Vidal-Ostos De Lara, Paz de Miguel Novoa, Elena López Mezquita, Felicia Alexandra Hanzu, Iban Aldecoa, Silvia Aznar, Cristina Lamas, Anna Aulinas, Anna Queralt Asla, Paola Gracia Gimeno, José María Recio Córdova, Mariola Aviles, Diego Asensio-Wandosel, Miguel Sampedro-Núñez, Rosa Camara, Miguel Paja Fano, Ignacio Ruz-Caracuel, Carmen Fajardo, Mónica Marazuela, Manel Puig-Domingo
AIM: To evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH/PRL-Pit-NET) and compare to those caused by a GH-Pit-NET. METHODS: A multicenter retrospective study of patients with acromegaly on treatment with pasireotide or pegvisomant. Patients were classified in two groups: GH/PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC; and GH-Pit-NETs when the previously mentioned criteria were not met...
May 1, 2024: Endocrine-related Cancer
#2
JOURNAL ARTICLE
Adrian F Daly, Albert Beckers
Pituitary gigantism is a rare manifestation of chronic growth hormone (GH) excess that begins before closure of the growth plates. Nearly half of pituitary gigantism patients have an identifiable genetic cause. X-linked acrogigantism (X-LAG; 10% of pituitary gigantism) typically begins during infancy and can lead to the tallest individuals described. In the 10 years since its discovery, about 40 patients have been identified. Patients with X-LAG usually develop mixed GH and prolactin macroadenomas with occasional hyperplasia that secrete copious amounts of GH, and frequently prolactin...
May 2, 2024: Endocrine Reviews
#3
JOURNAL ARTICLE
Shuai Li, Xiangyang Ye, Xiaolu Wen, Xuefen Yang, Li Wang, Kaiguo Gao, Hao Xiao, Zongyong Jiang
Arginine, which is metabolized into ornithine, proline, and nitric oxide, plays an important role in embryonic development. The present study was conducted to investigate the molecular mechanism of arginine in proliferation, differentiation, and physiological function of porcine trophoblast cells (pTr2) through metabolic pathways. The results showed that arginine significantly increased cell viability (P < 0.05). The addition of arginine had a quadratic tendency to increase the content of progesterone (P = 0...
April 30, 2024: BMC Veterinary Research
#4
JOURNAL ARTICLE
Iron deficiency in astrocytes alters cellular status and impacts on oligodendrocyte differentiation.
María Silvina Marcora, Vanesa Soledad Mattera, Pilar Goñi, Florencia Aybar, Jorge Daniel Correale, Juana Maria Pasquini
Iron deficiency (ID) has been shown to affect central nervous system (CNS) development and induce hypomyelination. Previous work from our laboratory in a gestational ID model showed that both oligodendrocyte (OLG) and astrocyte (AST) maturation was impaired. To explore the contribution of AST iron to the myelination process, we generated an in vitro ID model by silencing divalent metal transporter 1 (DMT1) in AST (siDMT1 AST) or treating AST with Fe3+ chelator deferoxamine (DFX; DFX AST). siDMT1 AST showed no changes in proliferation but remained immature...
April 2024: Journal of Neuroscience Research
#5
JOURNAL ARTICLE
Jennifer A Waters, Mikella Robinson, Omar Lujano-Olazaba, Cassidy Lucht, Samuel F Gilbert, Carrie D House
Ovarian cancer can metastasize to the omentum, which is associated with a complex tumor microenvironment. Omental stromal cells facilitate ovarian cancer colonization by secreting cytokines and growth factors. Improved understanding of the tumor supportive functions of specific cell populations in the omentum could identify strategies to prevent and treat ovarian cancer metastasis. Here, we showed that omental preadipocytes enhance the tumor initiation capacity of ovarian cancer cells. Secreted factors from preadipocytes supported cancer cell viability during nutrient and isolation stress and enabled prolonged proliferation...
April 18, 2024: Cancer Research
#6
JOURNAL ARTICLE
Noam Cohen-Rothschild, Naama Mizrahi, Berta Levavi-Sivan
The manipulation of the somatotropic axis, governing growth, has been a focus of numerous transgenic approaches aimed at developing fast-growing fish for research, medicine and aquaculture purposes. However, the excessively high growth hormone (GH) levels in these transgenic fish often result in deformities that impact both fish health and consumer acceptance. In an effort to mitigate these issues and synchronize exogenous GH expression with reproductive processes, we employed a novel transgenic construct driven by a tilapia luteinizing hormone (LH) promoter...
2024: Frontiers in Endocrinology
#7
JOURNAL ARTICLE
Christina Tatsi, Georgia Pitsava, Fabio R Faucz, Meg Keil, Constantine A Stratakis
CONTEXT: Carney complex (CNC) is a familial neoplasia syndrome associated with growth hormone (GH) excess (GHE). OBJECTIVE: To describe the frequency of GHE in a large cohort of patients with CNC, and to identify genotype-phenotype correlations. METHODS: Patients with CNC with at least one biochemical evaluation of GH secretion at our center from 1995-2021 (n=140) were included in the study. Diagnosis of GHE was based on levels of insulin-like growth factor-1 (IGF-1), GH suppression during oral glucose tolerance test (OGTT), GH stimulation after thyrotropin (TRH) administration and overnight GH secretion...
April 13, 2024: Journal of Clinical Endocrinology and Metabolism
#8
JOURNAL ARTICLE
Sheyda Nami, Azam Govahi, Nabaa Najjar, Samaneh Ghasemi, Farshid Rezaei, Fatemehsadat Amjadi, Gholamreza Taheripak
OBJECTIVE: This study investigated the metabolic status of the spent culture media from embryos of patients with repeated implantation failure (RIF) undergoing in vitro fertilization-intracytoplasmic sperm injection cycles in comparison with the embryos from healthy fertile women. METHODS: Metabolite levels in spent culture media were assessed and compared between embryos from RIF patients (n=35) and oocyte donors as controls (n=15). Protein levels of insulin-like growth factor 1 (IGF-1) were determined using Western blotting...
April 11, 2024: Clinical and Experimental Reproductive Medicine
#9
JOURNAL ARTICLE
Aleksandar Ivovic, Justin Hou Ming Yung, Andrei I Oprescu, Filip Vlavcheski, Yusaku Mori, S M Niazur Rahman, Wenyue Ye, Judith A Eversley, Michael B Wheeler, Minna Woo, Evangelia Tsiani, Adria Giacca
In the classical insulin target tissues liver, muscle and adipose tissue, chronically elevated levels of free fatty acids (FFA) impair insulin signaling. Insulin signaling molecules are also present in β-cells where they play a role in β-cell function. Therefore, inhibition of the insulin/IGF-1 pathway may be involved in fat-induced β-cell dysfunction. To address the role of β-cell insulin resistance in FFA-induced β-cell dysfunction we co-infused bisperoxovanadate (BPV) with oleate or olive oil for 48 h in rats...
April 5, 2024: Endocrinology
#10
REVIEW
Paa Kwesi Ankrah, Enock D Mensah, Kwabena Dabie, Caleb Mensah, Benjamin Akangbe, Jonathan Essuman
Aging is inevitable, but the lifespan (duration of life) and healthspan (healthy aging) vary greatly among individuals and across species. Unlocking the secrets behind these differences has captivated scientific curiosity for ages. This review presents relevant recent advances in genetics and cell biology that are shedding new light by untangling how subtle changes in conserved genes, pathways, and epigenetic factors influence organismal senescence and associated declines. Biogerontology is a complex and rapidly growing field aimed at elucidating genetic modifications that extend lifespan and healthspan...
March 2024: Curēus
#11
JOURNAL ARTICLE
Yu Wu, Jiuming Zhang, Wen Deng, Chaoting Mo, Yumei Liang, Kongqian Huang, Fan Xu, Fen Tang
Graves' ophthalmopathy (GO) is an extrathyroidal manifestation of Graves' disease, Orbital fibroblasts (OFs) are recognized as key players in GO pathogenesis, involved in orbital inflammation, tissue remodeling, and fibrosis. This study offers a primary exploration of cell behavior and characteristics on OFs from GO (GO-OFs), and compared to OFs from healthy control (HC-OFs). Results reveal that GO-OFs exhibit delayed migration from tissue fragments, while no significant difference in cell proliferation is observed between GO-OFs and HC-OFs...
April 15, 2024: Heliyon
#12
JOURNAL ARTICLE
Min Ge, Li Sun, Defeng Wang, Chunchao Hei, Tingjuan Huang, Zhongxin Xu, Qizhi Shuai
The use of stem cell-based treatment systems is prevalent in regenerative medicine. To enhance the regenerative capabilities of stem cells, growth factors are typically incorporated into the treatment system. Nonetheless, traditional hydrogel-encapsulated or heparinized scaffolds that bind factors have limitations. In this study, we prepared a biomaterial strategy using uniform poly(lactic-co-glycolic) acid (PLGA) microspheres (uPLGA-Ms) fabricated by microfluidic to sustain delivery of insulin-like growth factor 1 (IGF-1), a critical protein for hMSCs biological functions...
December 2024: Regenerative Therapy
#13
JOURNAL ARTICLE
Rachel L Gibbs, James A Wilson, Rebecca M Swanson, Joslyn K Beard, Zena M Hicks, Haley N Beer, Eileen S Marks-Nelson, Ty B Schmidt, Jessica L Petersen, Dustin T Yates
Stress-induced fetal programming diminishes β2 adrenergic tone, which coincides with intrauterine growth restriction ( IUGR ) and lifelong metabolic dysfunction. We determined if stimulating β2 adrenergic activity in IUGR-born lambs would improve metabolic outcomes. IUGR lambs that received daily injections of saline or the β2 agonist clenbuterol from birth to 60 days were compared with controls from pair-fed thermoneutral pregnancies. As juveniles, IUGR lambs exhibited systemic inflammation and robust metabolic dysfunction, including greater ( p < 0...
March 7, 2024: Metabolites
#14
REVIEW
Robert C Baxter
The acid-labile subunit (ALS) of the insulin-like growth factor (IGF) binding protein (IGFBP) complex, encoded in humans by IGFALS, has a vital role in regulating the endocrine transport and bioavailability of IGF-1 and IGF-2. Accordingly, ALS has a considerable influence on postnatal growth and metabolism. ALS is a leucine-rich glycoprotein that forms high-affinity ternary complexes with IGFBP-3 or IGFBP-5 when they are occupied by either IGF-1 or IGF-2. These complexes constitute a stable reservoir of circulating IGFs, blocking the potentially hypoglycaemic activity of unbound IGFs...
March 21, 2024: Nature Reviews. Endocrinology
#15
JOURNAL ARTICLE
Maria Andrea Lanzetta, Eva Dalla Bona, Gianluca Tamaro, Viviana Vidonis, Giada Vittori, Elena Faleschini, Egidio Barbi, Gianluca Tornese
INTRODUCTION: It has been proposed that not all children with short stature displaying an inadequate response to tests for growth hormone (GH) secretion truly suffer from GH deficiency (GHD). Only children with a monogenic cause of GHD or an identifiable combined hormonal deficiency or anatomical anomaly in the hypothalamic-pituitary axis should be considered definite GHD (dGHD). The remaining patients can be defined as a separate group of patients, "short stature unresponsive to stimulation tests" (SUS)...
2024: Frontiers in Endocrinology
#16
JOURNAL ARTICLE
Xiaonan Guo, Wenjing Hu, Xiaorui Lyu, Hanyuan Xu, Huijuan Zhu, Hui Pan, Linjie Wang, Hongbo Yang, Gong Fengying
OBJECTIVE: Patients with growth hormone deficiency (GHD) with inadequate growth hormone levels are often correlated with nonalcoholic fatty liver disease (NAFLD). However, potential mechanism of how GHD influences liver function remains obscure. Thus, we aimed to perform hepatic metabolomics in Lewis dwarf rats, a classical model of isolated GH-deficient rat, to evaluate characterizations of hepatic metabolic profiles and explore their relations with liver functions. METHODS: Lewis dwarf homozygous (dw/dw) rats at 37 weeks (five females and five males), and Lewis dwarf heterozygous (dw/+) rats at 37 weeks (five females and five males) were analyzed in our study...
March 1, 2024: Endocrine Connections
#17
JOURNAL ARTICLE
Yanan Wang, Jingjing Chen, Chen Wang, Tong Chen, Ling He
BACKGROUND: G protein-coupled receptor 40 (GPR40) is a potential drug target for Alzheimer's disease (AD), and its agonist GW9508 ameliorates cognitive impairment by intravenous administration. OBJECTIVES: The present study was conducted to investigate the efficacy of GW9508 administered peripherally on cognitive dysfunction in streptozotocin (STZ)-induced AD mice. METHODS: Seventy male ICR mice were randomly divided into seven groups: vehicle sham group, model, Donepezil, GW9508-L, GW9508-M, GW9508-H, and GW1100 + GW9508-H groups, and administered either vehicle (artificial cerebrospinal fluid [aCSF]) or STZ (3 mg/kg in the vehicle) once a day (9:00 a...
March 14, 2024: Fundamental & Clinical Pharmacology
#18
JOURNAL ARTICLE
Linus Haberbosch, James MacFarlane, Olympia Koulouri, Daniel Gillett, Andrew S Powlson, Sue Oddy, David J Halsall, Kevin A Huynh, Jonathan Jones, Heok K Cheow, Joachim Spranger, Knut Mai, Christian Strasburger, Richard J Mannion, Mark Gurnell
BACKGROUND: L-[methyl-11C]-methionine-positron emission tomography (Met-PET) is a potentially important imaging adjunct in the diagnostic workup of pituitary adenomas, including somatotroph tumours. Met-PET can identify residual or occult disease and make definitive therapies accessible to a subgroup of patients who would otherwise require lifelong medical therapy. However, existing data on its use are still limited to small case series. Here, we report the largest single centre experience (N=61) in acromegaly...
March 14, 2024: European Journal of Endocrinology
#19
JOURNAL ARTICLE
Zhengzheng Ju, Fan Cui, Zheng Mao, Zhen Li, Xiayu Yi, Jingjing Zhou, Jinjin Cao, Xiaoqin Li, Zengkun Qian
Previous studies have found that miR-335 is highly expressed in type II diabetes mellitus (T2DM) models and is related to insulin secretion, but there are few studies on the regulatory effects of miR-335-3p on insulin resistance and macrophage polarization in T2DM patients. This study aims to explore the effects of miR-335-3p on insulin resistance and macrophage polarization in T2DM patients. Blood glucose (insulin tolerance tests, glucose tolerance tests) and body weight of the T2DM model were measured; macrophages from adipose tissue were isolated and cultured, and the number of macrophages was detected by F4/80 immunofluorescence assay; the Real-time quantitative polymerase chain reaction (qPCR) assay and Western blot assay were used to detect the miR-335-3p expression levels, insulin-like growth factor 1 (IGF-1), M1-polarizing genes (inducible nitric oxide synthase [iNOS] and TNF-α) as well as M2-polarizing genes (IL-10 and ARG-1)...
2024: Open Medicine (Warsaw, Poland)
#20
REVIEW
Ilan Shimon
Cabergoline is an ergot derivative long-acting dopamine receptor 2 (DR2) selective agonist administered orally and widely used for the treatment of prolactin-secreting adenomas and Parkinson's disease. DR2 is expressed in most somatotroph adenomas. In acromegaly, cabergoline is used off-label and its role is limited by the relatively modest efficacy for achieving hormonal remission and thus, it is largely indicated in patients with mild elevation of GH/IGF-I postoperatively. It can be given as monotherapy, usually at a higher weekly dose than usually required to treat prolactinomas, but also as an add-on treatment in patients partially responding to the somatostatin receptor ligands octreotide or lanreotide...
February 28, 2024: Best Practice & Research. Clinical Endocrinology & Metabolism
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
